Read, Watch or Listen

Bank of America analyst Anna Lizzul maintains a buy rating on Kenvue stock, citing a recent sell-off as a buying opportunity. Despite a year-to-date decline of 12.8% and a recent drop following a Wall Street Journal report linking Tylenol to autism, Lizzul believes the negative impact will be minimal. She points to Kenvue's new leadership, revised 2025 guidance, and the FDA's previous rejection of a causality link between acetaminophen and autism. Lizzul values Kenvue at a 13x CY26e EV/EBITDA multiple, suggesting significant upside potential.

Prepared by Christopher Adams and reviewed by editorial team.